Regulus Therapeutics Inc (RGLS) Major Shareholder Peter J. Barris Acquires 1,136,704 Shares

Regulus Therapeutics Inc (NASDAQ:RGLS) major shareholder Peter J. Barris acquired 1,136,704 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The stock was acquired at an average price of $1.08 per share, for a total transaction of $1,227,640.32. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

NASDAQ:RGLS opened at $1.28 on Friday. The stock has a market capitalization of $12.94 million, a price-to-earnings ratio of -0.23 and a beta of 2.26. Regulus Therapeutics Inc has a 12-month low of $0.80 and a 12-month high of $9.48.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.06). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $7.01 million. Regulus Therapeutics had a negative net margin of 67,650.01% and a negative return on equity of 671.46%. As a group, equities research analysts predict that Regulus Therapeutics Inc will post -4.28 earnings per share for the current year.

A number of research analysts have issued reports on the stock. Wedbush set a $1.00 target price on shares of Regulus Therapeutics and gave the company a “hold” rating in a report on Wednesday. ValuEngine lowered shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Friday, March 29th. Finally, Wells Fargo & Co reduced their target price on shares of Regulus Therapeutics from $6.00 to $1.50 and set a “market perform” rating on the stock in a report on Tuesday, March 19th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. Regulus Therapeutics has an average rating of “Hold” and an average price target of $1.06.

Large investors have recently added to or reduced their stakes in the business. Wedbush Securities Inc. lifted its holdings in shares of Regulus Therapeutics by 32.8% during the 1st quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,751 shares during the period. Virtu Financial LLC purchased a new position in shares of Regulus Therapeutics during the 1st quarter worth about $68,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Regulus Therapeutics by 396.3% during the 3rd quarter. Renaissance Technologies LLC now owns 595,501 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 475,512 shares during the period. Institutional investors own 25.17% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Regulus Therapeutics Inc (RGLS) Major Shareholder Peter J. Barris Acquires 1,136,704 Shares” was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/regulus-therapeutics-inc-rgls-major-shareholder-peter-j-barris-acquires-1136704-shares.html.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Featured Story: Asset Allocation, Balancing Your Investments

Insider Buying and Selling by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.